Skip to content

Author

V. Di Stefano

We have 3 of 199 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Reduction of interleukin-6 levels in patients with Friedreich's Ataxia treated with omaveloxolone.

Omav confirmed a favorable safety and tolerability profile in adult patients with FRDA in a real-world setting after 48 weeks of treatment, and a sustained reduction in IL-6 levels supports a potential direct immunomodulatory effect of the drug, consistent with its proposed disease-modifying activity.

V. Di Stefano, Salvatore Maria Lima, S. Campo et al. · 0 citations
Open access Sep 2026

Assessing the Clinical Relevance of Blood Soluble Triggering Receptor Expressed on Myeloid Cells 2 in Neurological Diseases

Blood sTREM2 does not directly mirror central nervous system microglial activation but may reflect peripheral immune dynamics, warranting further investigation into its role as a biomarker of systemic immune dysfunction in neurodegenerative diseases.

L. Agnello, C. Gambino, Giuseppe Salemi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.